Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results

Clinical Cancer Research

Volumn 2, Issue 6, 1996, Pages 963-972

  Brown, Mark T ^a   Coleman, R Edward ^a   Friedman, Allan H ^a   Friedman, Henry S ^a   McLendon, Roger E ^a   Reiman, Robert ^a   Felsberg, Gary J ^a   Tien, Robert D ^a   Bigner, Sandra H ^a   Zalutsky, Michael R ^a   Zhao, Xiao G ^a   Wikstrand, Carol J ^a   Pegram, Charles N ^a   Herndon II, James E ^a   Vick, Nicholas A ^b   Paleologos, Nina ^b   Fredericks, Ruth K ^c   Schold Jr , S Clifford ^d   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; IOPAMIDOL; LIOTHYRONINE SODIUM; MONOCLONAL ANTIBODY 81C6; TENASCIN; TENASCIN ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANIMAL; ARTICLE; BRAIN TUMOR; CLINICAL TRIAL; FEMALE; HUMAN; IMMUNOLOGY; MALE; MENINGIOMA; MIDDLE AGED; MORTALITY; MOUSE; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; RADIATION DOSE; RADIOIMMUNOTHERAPY; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; EPENDYMOMA; GLIOBLASTOMA; INTRATHECAL DRUG ADMINISTRATION; MEDULLOBLASTOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHOOL CHILD; SUBARACHNOID SPACE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CHILD, PRESCHOOL; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MENINGEAL NEOPLASMS; MICE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 0029657596     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Wasserstrom, W. R., Glass, J. P., and Posner, J. B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer (Phila.), 49: 759-772, 1982.
2. Pfeffer, M. R., Wygoda, M., and Siegal, T. Leptomeningeal metastases: treatment results in 98 consecutive patients. Isr. J. Med. Sci., 24: 611-618, 1988.
3. Siegal, T., Lossos, A., and Pfeffer, M. R. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology, 44: 1463-1469, 1994.
4. Grossman, S. A., and Moynihan, T. J. Neoplastic meningitis. Neurol. Clin., 9: 843-856, 1991.
5. Boogerd, W., Hart, A. A. M., van der Sande, J. J., and Engelsman, E. Meningeal carcinomatosis in breast cancer: prognostic factors and influence of treatment. Cancer (Phila.), 67: 1685-1695, 1991.
6. Twijnstra, A., and Glass, J. P. Leptomeningeal metastasis from solid extracranial tumors: clinical diagnosis and management. In: A. Twijnstra, A. Keyser, and B. W. Ongerboer de Visser (eds.), Neurooncology: Primary Tumors and Neurological Complications of Cancer, pp. 257-265. Amsterdam: Elsevier, 1993.
7. Yung, W-k. A., Horten, B. C., and Shapiro, W. R. Meningeal gliomatosis: a review of 12 cases. Ann. Neurol., 8: 605-608, 1980.
8. Mahaley, M. S., Jr. Neurooncology index and review (adult primary brain tumors) Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy. J. Neuro-Oncol., 11: 85-147, 1991.
9. Levin, V. A., Resser, K. J., McGrath, L., Vestnys, P., Nutik, S., and Wilson, C. B. PCNU treatment for recurrent malignant gliomas. Cancer Treat. Rep., 68: 969-973, 1984.
10. Schold, S. C., Jr., Mahaley, M. S., Jr., Vick, N. A., Friedman, H. S., Burger, P. C., DeLong, E. R., Albright, R. E., Jr., Bullard, D. E., Khandekar, J. D., Cairncross, J. G., Macdonald, D. R., and Falletta, J. M. Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms. J. Clin. Oncol., 5: 464-471, 1987.
11. Miller, R. A., Oseroff, A. R., Stratte, P. E., and Levy, R. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma Blood, 62: 988-995, 1983.
12. Embleton, M. J., Rowland, G. F., Simmonds, R. G., Jacobs, E., Marsden, C H., and Baldwin, R. W. Selective cytotoxicity against human tumor cells by a vindesine-monoclonal antibody conjugate. Br. J Cancer, 47: 43-49, 1983.
13. Jansen, F. K., Blythman, H. E., Carriere, D., Casellas, P., Gros, O., Gros, P., Laurent, J. C., Paolucci, F., Pau, B., Poncelet, P., Richer, G., Vidal, H., and Voisin, G. A. Immunotoxins. Hybrid molecules combining high specificity and potent cytotoxicity Immunol. Rev., 62: 185-216, 1982.
14. Thorpe, P. E., Brown, A. N. F., Bremmer, J. A. G., Jr., Foxwell, B. M. J., and Stirpe, F. An immunotoxin composed of monoclonal anti-Thy-1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent anti-tumour effects in vitro and in vivo. J. Natl. Cancer Inst., 75: 151-159, 1985.
15. Bourdon, M. A., Coleman, R. E., Blasberg, R. G., Groothuis, D. R., and Bigner, D. D. Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis. Anticancer Res., 4: 133-140, 1984.
16. Bullard, D. E., Adams, C. J., Coleman, R. E., and Bigner, D. D. In vivo imaging of intracranial human glioma xenografts comparing specific with non-specific radiolabeled monoclonal antibodies. J. Neurosurg., 64: 257-262, 1986.
17. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res., 49: 2807-2813, 1989.
18. Zalutsky, M. R., Moseley, R. P., Benjamin, J. C., Colapinto, E. V., Fuller, G. N., Coakham, H. B., and Bigner, D. D. Monoclonal antibody and F(ab′)2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res., 50: 4105-4110, 1990.
19. Kemshead, J. T., Papanastassiou, V., Coakham, H. B., and Pizer, B. L. Monoclonal antibodies in the treatment of central nervous system malignancies. Eur. J. Cancer, 28: 511-513, 1992.
20. Jain, R K., and Baxter, L. T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res., 48: 7022-7032, 1988.
21. Lashford, L. S., Davies, A. G., Richardson, R. B., Bourne, S. P., Bullimore, J. A., Eckert, H., Kemshead, J. T., and Coakham, H. B. A pilot study of 131-I monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer (Phila.), 61: 857-868, 1988.
22. Moseley, R. P., Davies, A. G. Richardson, R. B., Zalutsky, M., Carrell, S., Fabre, J., Slack, N., Bullimore, J., Pizer, B., Papanastassiou, V., Kemshead, J. T., Coakham, H. B., and Lashford, L. S. Intrathecal administration of 131-I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br. J. Cancer, 62: 637-642, 1990.
23. Bourdon, M. A., Wikstrand, C. J., Furthmayr, H., Matthews, T. J., and Bigner, D. D Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res., 43: 2796-2805, 1983.
24. Director. Office of Biologics Research and Research, Center for Drugs and Biologics, Points to consider in the manufacture and testing of monoclonal antibody products for human use (1987). United States Food and Drug Administration.
25. Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., and Bunn, P. A., Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods, 72: 77-89, 1984.
26. Miller, W. T., and Barrett, A. Dosimetric model for antibody targeted radionuclide therapy of tumor cells in cerebrospinal fluid. Cancer Res., 50 (Suppl. 3): 1043s-1048s, 1990.
27. Terpstra, T. J. The asymptotic normality and consistency of Kendall's test against trend, when ties are present in one ranking. Indag. Math, 14: 327-333, 1952.
28. Jonckheere, A. R. A distribution-free k-sample test against ordered alternatives. Biometrika, 41: 133-145, 1954.
29. Riva, P., Arista, A., Tison, V., Sturiale, C., Franceschi, G., Spinelli, A., Riva, N., Casi, M., Moscatelli, G., and Frattarelli, M. Intralesional radioimmunotherapy of malignant gliomas. Cancer (Phila.), 73: 1076-1082, 1994.
30. Murphy-Ullrich, J. E., Lightner, V. A., Aukhil, I., Yan, Y. Z., Erickson, H. P., and Höök, M. Focal adhesion integrity is down-regulated by the alternatively spliced domain of human tenascin. J. Cell Biol., 115: 1127-1156, 1991
31. Wikstrand, C. J., McLendon, R. E., Carrel, S., Kemshead, J. T., Mach, J-P., Coakham, H. B., deTribolet, N., Bullard, D. E., Zalutsky, M. R., and Bigner, D. D. Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model. J. Neuroimmunol., 15: 37-56, 1987.
32. Schold, S. C., Jr., Zalutsky, M. R., Coleman, R. E., Glantz, M. J., Friedman, A. H., Jaszczak, R. J., Bigner, S. H., and Bigner, D. D. Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. Invest. Radiol., 28: 488-496, 1993.
33. 131I-labeled anti-tenascin monoclonal antibody 81C6. Cancer Res., 48: 2904-2910, 1988.
34. Lee, Y-S., Bullard, D. E., Zalutsky, M. R., Coleman, R. E., Wikstrand, C. J., Friedman, H. S., Colapinto, E. V., and Bigner, D. D. Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131-I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. Cancer Res., 48: 559-566, 1988.
35. Moseley, R. P., Papanastassiou, V., Zalutsky, M. R., Ashpole, R. D., Evans, S., Bigner, D. D., and Kemshead, J. T. Immunoreactivity, pharmacokinetics, and bone marrow dosimetry of intrathecal radioimmunoconjugates. Intl. J. Cancer, 52: 38-43, 1992.
36. Richardson, R. B., Kemshead, J. T., Davies, A. G., Staddon, G. E., Jackson, P. O., Coakham, H. B., and Lashford, L. S. Dosimetry of intrathecal iodine 131 monoclonal antibody in cases of neoplastic meningitis. Eur. J. Nucl. Med., 17: 42-48, 1990.